29.08.2018 19:43:22

Glaukos Stock Up After Competitor Recalls Glaucoma Surgical Device

(RTTNews) - Shares of Glaukos Corp. (GKOS) surged nearly 35% Wednesday after drug maker Novartis AG's (NVS) Alcon eye-care division voluntarily recalled its CyPass Micro-Stent, a surgical device used to treat glaucoma.

Alcon, the eye care unit of Novartis, announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. Alcon also advised surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon.

The move is based on an analysis of five-year post-surgery data from the long-term safety study. At five years, the CyPass Micro-Stent group experienced statistically significant endothelial cell loss compared to the group who underwent cataract surgery alone.

The US Food and Drug Administration or FDA approved the CyPass Micro-Stent in July 2016 for use in conjunction with cataract surgery in adult patients with mild-to-moderate primary open-angle glaucoma based on the results of the landmark two-year COMPASS study.

Glaukos, the maker of iStent--a device used in micro-invasive glaucoma surgery--had benefited from no direct competition in the U.S. for several years after it launched in 2012.

Glaukos shares are currently trading at $60.31, up $15.55 or 34.75%, on the NYSE.

Analysen zu Glaukos Corpmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Glaukos Corp 149,00 0,00% Glaukos Corp